… The primary objective of this study was to characterize the pharmacokinetics of erlotinib in a
… on its pharmacokinetics. The second objective was to evaluate the relationship of erlotinib …

… Erlotinib is used to treat non-small-cell lung cancer (NSCLC), … the relationship between
erlotinib plasma concentrations and … and tumor growth inhibition in a human non-small-cell lung …

… Erlotinib is an oral first-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor approved for non–small cell lung cancers (… the pharmacokinetic profile of erlotinib in …

… with erlotinib. Several explanations have been suggested, including pharmacokinetic and
… The purposes of this study were to characterize erlotinib pharmacokinetic and to correlate …

… variations on the clinical outcomes of erlotinib remains fully investigated. The …
pharmacokinetics/pharmacodynamics of erlotinib in Japanese patients with non-small cell lung …

… schedule of erlotinib and pemetrexed for the treatment of relapsed non–small cell lung cancer
(… Experimental Design: Human NSCLC cell lines, with variable expression of the known …

… In agreement with data from a phase II trial with erlotinib in patients with non-small cell
lung cancer, 17 findings from recent phase II studies with two anti-HER1/EGFR monoclonal …

… inhibitors erlotinib and gefitinib in EGFR mutation-positive non-small-cell lung cancer could
be … Erlotinib has a seventimes greater AUC than does gefitinib, which might explain its better …

… This approach showed that the metabolic clearance of erlotinib occurs … the pharmacokinetic
rate of erlotinib elimination from the body. We considered a function governing the erlotinib …

… pharmacokinetics of erlotinib were affected by the coadministration of dasatinib, we compared
the pharmacokinetic parameters of erlotinib … because similar pharmacokinetic parameter …